Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
Bottom Line: Conventional treatments for PTLD are often successful, but risk organ rejection and cause significant side effects.Both cases of EBV-associated non-haematopoietic sarcoma receiving cells failed to achieve complete remission.Thus, this third party donor-derived EBV-specific CTL cell bank can supply most patients with appropriately matched cells and most recipients have good outcomes.
Affiliation: Scottish National Blood Transfusion Service, Aberdeen, London, UK; University of Aberdeen, Aberdeen, London, UK.Show MeSH
Related in: MedlinePlus
Mentions: To date, 36 HLA matching requests have been processed and 32 allocation reviews completed. The minimum number of antigens shared for both HLA class I and class II combined was 2/10 and the maximum 9/10 (Fig2). For the CTLs infused, the minimum number of antigens shared was 3/10 and the maximum 9/10. Figure2 understates the degree of matching somewhat, as information was only available at class I loci for two of the pairs (neither patient received infusions). There was a median of three class I matches and two class II matches. The degree of matching for class II improved with time as the numbers within the bank built up, but this effect was not apparent for class I. Those that were issued had a slightly higher degree of matching (3·0 vs. 2·8 class I and 1·9 vs. 1·8 class II).
Affiliation: Scottish National Blood Transfusion Service, Aberdeen, London, UK; University of Aberdeen, Aberdeen, London, UK.